RNA-seq of human aortic smooth muscle cells treated with recombinant sST2 and angiotensin II
To elucidate the mechanism by which sST2 contributes to aortic disease, human aortic smooth muscle cells were exposed to recombinant sST2 and angiotensin II. Cells were allocated to two 24-hour treatment groups(n = 3): angiotensin II alone or the combination of recombinant sST2 plus angiotensin II, followed by RNA-seq analysis.